These arguments have been taken up by some conservative members of Congress, who are now demanding that NIH justify how it divvies up the funding for various diseases. Last year, Representative Ernest Istook (R-OK), a member of Porter's NIH appropriations subcommittee, released graphs put together by James Crapo, a well-known pulmonary researcher and pathologist at Duke University, indicating that major diseases are not getting their fair share of funding increases. In a subcomui * 0 6. S. _ . S * -L ~~~~~~~~~~~~~~~~~~~~~~~~C mittee hearing earlier this year, Istook took up the subject again with a reference to the large sum NIH is spending on AIDS (see sidebar). Other legislators are using similar logic to advance their own causes. Representative Henry Bonilla (R-TX), for example, whose Hispanic constituency is affected by a high incidence of diabetes, argues that NIH should be earmarking more for diabetes research. All this is putting NIH on the spot. NIH director Harold Varmus calls such cost-perpatient rationales "confusing" and "simplistic." He says the data come from different sources and are based on variable definitions. Seeking a fair share In the weeks leading up to those hearings, Congress will hear directly from groups that believe they are being shortchanged. No group has taken up the cudgels on its own behalf more determinedly than the AHA. Last year, advocates of heart research were so aggressive in making comparisons between their field and AIDS research that they drew criticism from Varmus behind the scenes. Varmus says that he has met with AHA President Jan Breslow-a well-regarded heartdisease geneticist at Rockefeller University in New York City and a member of the National Academy of Sciences-and that "we have a much better understanding ... at this point." Claude Lenfant, director of the National Heart, Lung, and Blood Institute (NHLBI), says he has also tried to temper Breslow's rhetoric. But Breslow is as insistent as ever.
Breslow says he is "appalled" at the deterioration of support for cardiovascular studies over the past decade, claiming they have been "gutted" by neglect. "The field has been depleted of young investigators," Breslow says, and he aims to combat the "myth that heart disease is going away. lion suffer congestive heart failure, and this disease remains the nation's number-one killer. Breslow plans to argue in testimony to Porter's panel this week that heart-related research suffered "a serious shortfall" at NHLBI and the National Institute of Neurological Disorders and Stroke (NINDS) during the decade when the AIDS budget grew rapidly. The AHA claims that while funding for NIH overall has increased 35.9% in constant dollars since 1986, the heart program at NHLBI and NINDS declined 5.5%. Breslow is planning to ask that NHLBI's budget be raised from $1.4 billion in 1997 to $1.65 billion in 1998. Asked if AHA is targeting the AIDS set-aside, Breslow says, "We're not trying to take anything away from other diseases." But he insists: "We are very upset that we have been neglected ... and we're not going to take it anymore."
The AHA isn't the only group singing the blues. The JDF is arguing that diabetes research, too, has been overlooked. The JDF is pushing for special increases for the institute that chiefly funds its area-the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is using a different tactic, however-that of an eager partner demanding more attention. The JDF is unusual in that it plans to donate $67 million over a decade to projects that are peer reviewed, coselected, and co-funded by NIH.
On 1 April, JDF hired Robert Goldstein, an extramural research director for immunology at the National Institute of Allergy and Infectious Diseases, to be its own director of research. He is teaming up with the management firm of McKinsey & Co. to conduct a review of diabetes funding and develop a strategic plan for diabetes. JDF officials say NIDDK funding has grown only 53% in a 10-year period when overall NIH funding has increased 97%. And Goldstein says that when parents of a child with diabetes see these numbers, they ask, "Why isn't my child just as important" as other patients.
The JDF wants to increase funding for NIH by 9%, for NIDDK by 12%, and for diabetes research by 15%. Advocates have already prepared draft legislation to mandate a national diabetes research plan.
Another targeted bill-the Morris K. Udall Parkinson's Research and Education Actwas introduced into Congress last week. It would authorize NIH to spend $100 million on Parkinson's research (NIH now spends about $32 million) and create 10 special centers around the country for collaborative research. More than 100 members of the House and 34 senators are co-sponsors.
And it's not just the arguably neglected who are out campaigning. On 8 April, the National Breast Cancer Coalition, which has helped nudge hundreds of millions of dollars' worth of earmarks through Congress, announced that it is forming a political action committee. The purpose, says coalition president Fran Visco, a Philadelphia attorney, is to do "electioneering"-such as registering voters-that is not permitted to regular nonprofits. "We wanted to let our voting members know who is really supporting us," says Visco.
No more Mr. Nice Guy It may seem odd that this new "targeted advocacy" is intensifying while NIH's budget is increasing. Usually, coalitions start to fragment when resources are declining. David Moore, govemment liaison for the Association of American Medical Colleges, explains that after "two extraordinary years, with huge increases [for NIH]," more money has been "pumped into the system," but it hasn't been distributed at the same rate to all constituencies. The result, he says, is an "increasing level of frustration, ... some of it justified," among those who feel that they have been left behind. The report also recommends following up on recent spectacular successes in finding galaxies near the time they were bom. Bunner calls it "strong endorsement for the [proposed] Next Generation Space Telescope and for a U.S. role in the European FIRST" -the planned Far Infrared and Submillimeter Space Telescope.
While listing the search for more planets around other stars as their third priority, the astronomers also urge some restraint, recommending that NASA hold off on trying to image planets like Earth. The planets currently being found are giants, the size of Jupiter or larger. NASA's proposed 1998 budget includes finding for a small, space-based interferometer-a linked array of telescopes-which could pick out indirect clues to planets as small as Earth. Actually photographing such planets, however, would require a large, costly interferometer positioned out near Jupiter, a dream that Thaddeus says should be deferred. "First, we should put our arms around as many planets as we can," he says, "before doing the very difficult thing of finding terrestrials."
The final priority he and his colleagues cite is measuring the properties of black holes-objects that have recently moved from the domain of theory to that of observation. Both star-sized black holes and the giant black holes at the centers of some galaxies trigger bursts of x-rays and gamma radiation as they suck in material. Bunner says the recommendation that NASA focus on the study of these objects supports the need for the Gamma-Ray Large Area Space Telescope and the High Throughput X-ray Spectroscopy Mission, two proposed midsize projects.
The astronomy community hasn't had a chance to react yet to the NRC committee's assessment of its field. But Bunner says, "We're pleased with the process-it wasn't cantankerous and it achieved consensus." Whether these science recommendations will guide NRC's next decade report is not clear. "The decade process, once started, has a life of its own," says John Bahcall of the Institute for Advanced Study in Princeton, New Jersey, who was chair of the previous decade report. But Thaddeus is hopeful: "I suppose the next decade committee could throw this in the wastebasket. But in a well-ordered world, this would be grist for their mill." -Ann Finkbeiner
Ann Finkbeiner is a science writer in Baltimore.
